Exact Sciences Corp. stock (US30063P1057): Q1 2026 earnings and screening advancements

Exact Sciences Corp. reported first quarter 2026 financial results, highlighting growth in Cologuard and Oncotype DX amid ongoing investments in precision oncology. Cash position strengthened to support pipeline expansion.

Exact Sciences Corp., a leader in precision oncology diagnostics, released its first quarter 2026 financial results on May 8, 2026. The company posted revenue of $1.62 billion, up 12% year-over-year, driven by strong performance in its core screening and cancer diagnostics segments, according to Exact Sciences IR as of 05/08/2026. Key metrics included adjusted EBITDA of $180 million, reflecting operational efficiency gains.

CEO Kevin Conroy emphasized the company's commitment to expanding access to non-invasive cancer screening, with Cologuard Plus adoption accelerating. The stock traded at $52.45 USD on 05/10/2026 on Nasdaq, according to Yahoo Finance as of 05/10/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Exact Sciences Corp.
• Sector/industry: Healthcare / Diagnostics
• Headquarters/country: Madison, WI / USA
• Core markets: US, Europe
• Key revenue drivers: Cologuard, Oncotype DX
• Home exchange/listing venue: Nasdaq (EXAS)
• Trading currency: USD

Exact Sciences Corp.: core business model

Exact Sciences Corp. develops and markets molecular tests for cancer screening and diagnosis. Its flagship product, Cologuard, is a non-invasive stool-based test for colorectal cancer screening, approved by the FDA and covered by Medicare for average-risk adults aged 45-85. The company generated $815 million in screening revenue for Q1 2026, up 15% from the prior year, per the earnings release dated 05/08/2026.

Oncotype DX tests provide genomic profiling for breast, prostate, and colon cancers, guiding treatment decisions. Precision Oncology revenue reached $647 million in the quarter, supported by expanded lab capacity and reimbursement wins. Exact Sciences operates primarily in the US market, where it holds significant share in non-invasive screening, making it relevant for US investors tracking healthcare innovation.

Main revenue and product drivers for Exact Sciences Corp.

Cologuard remains the primary revenue driver, with over 2 million tests delivered in Q1 2026, reflecting higher screening volumes post-guideline changes lowering the starting age to 45. The next-generation Cologuard Plus, launched in 2025, boasts improved specificity, driving adoption among primary care providers. Revenue growth was bolstered by a 20% increase in completed tests year-over-year, as reported in the Q1 2026 financials.

Oncotype DX and other diagnostics contribute steady growth, with therapy selection tests gaining traction amid personalized medicine trends. R&D expenses rose 10% to $120 million, funding pipeline candidates like multi-cancer detection tests. For US investors, Exact Sciences' exposure to the $10 billion US colorectal screening market underscores its growth potential.

Industry trends and competitive position

The precision diagnostics sector is expanding at 12% CAGR through 2030, per Grand View Research as of 2024, driven by aging populations and genetic testing adoption. Exact Sciences competes with Guardant Health and Guardant360 in liquid biopsy but leads in stool-based screening with Cologuard's proven outcomes data from the DeeP-C study.

Reimbursement remains key, with recent CMS expansions enhancing accessibility. The company's 1,200+ sales reps target physician offices, differentiating it from lab-centric rivals. For US portfolios, Exact Sciences offers exposure to defensive healthcare growth amid economic cycles.

Why Exact Sciences Corp. matters for US investors

Listed on Nasdaq under EXAS, Exact Sciences benefits from strong US healthcare spending, projected at 18% of GDP by 2030. Its products address critical needs in cancer prevention, a priority for Medicare and private insurers. The company's Madison, WI headquarters supports proximity to US regulatory bodies and key accounts.

Conclusion

Exact Sciences Corp. delivered solid Q1 2026 results with revenue growth and pipeline momentum, positioning it well in precision diagnostics. Investors should monitor upcoming trial data and reimbursement developments for insights into sustained performance. Market dynamics in screening continue to evolve, influencing long-term trajectories.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.